Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives
Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced that it has been chosen by a medium sized pharmaceutical company for cardiac safety evaluation comprising multiple Thorough QT (TQT) Studies.
iCardiac will use its FDA accepted Highly Automated QT method for all contracted studies in addition to using iCardiac's QTbtb(sm) method for avoiding false positives. The sponsor selected iCardiac because of both iCardiac's cardiac safety expertise in relation to complex drug development programs as well as the extensive validation of iCardiac's COMPAS technology. COMPAS Highly Automated QT leads the industry in validation and deployments covering over 1.5 million ECGs analyzed with partners including pharmaceutical companies, academia, regulators, as well as having been cross validated with result from five leading ECG core labs.
"We are enthusiastic about the markets continued acceptance of iCardiac's Highly Automated QT solution," said Sasha Latypova, Executive Vice President. "In addition to increasing the robustness of cardiac safety evaluation and reducing the likelihood of false positives through the use of iCardiac's proprietary QTbtb method, the sponsor will realize increased economic efficiencies in comparison to traditional QT studies."
About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.
Read the full story at http://www.prweb.com/releases/tqt/cardiacsafety/prweb2526064.htm.
Copyright©2009 Vocus, Inc.
All rights reserved